S.V. AKINSHINA, V.O. BITSADZE, M.D. ANDREEVA, A.D. MAKATSARIYA

I.M. Sechenov First Moscow State Medical University,8 Trubetskaya St., bld.2, Moscow, Russian Federation 119991

Akinshina S.V. — Candidate of Medical Science, research associate of the Department of Obstetrics and Gynaecology of Public Health faculty, 62 Zemlyanoy Val St., bld.1., Moscow, Russian Federation 109004, tel. +7-903-238-80-48, e-mail: gemostasis@mail.ru¹

Bitsadze V.O. — D.Med.Sc., Professor of the Department of Obstetrics and Gynaecology of Public Health faculty, 62 Zemlyanoy Val St., bld.1., Moscow, Russian Federation 109004, tel. +7-926-231-38-29, e-mail: gemostasis@mail.ru¹

Andreeva M.D. — Candidate of Medical Science, doctoral candidate of the Department of Obstetrics and Gynaecology of Public Health faculty, 62 Zemlyanoy Val St., bld.1., Moscow, Russian Federation 109004, tel. +7-918-388-61-11, e-mail: gemostasis@mail.ru¹

Makatsariya A.D. — D.Med.Sc., Professor, corresponding member of RAMS, Head of the Department of Obstetrics and Gynaecology of Public Health faculty, 62 Zemlyanoy Val St., bld.1., Moscow, Russian Federation 109004, tel.+7-903-728-08-97, e-mail: gemostasis@mail.ru¹

At the present timethrombotic thrombocytopenic purpura (TTP), hemolytic-uremic syndrome, heparin induced thrombocytopenia and HELLP syndrome are refered to thrombotic microangiopathy.One of the major triggers for the emergence of thrombotic microangiopathy is pregnancy. This fact opens great prospects for studying the pathogenesis of thrombotic microangiopathy in the context of physiological changes in hemostasis during pregnancy. At the same time, the discovery of the molecular mechanisms of thrombotic microangiopathy, allows new insights on the pathogenesis of thrombotic complications associated with pregnancy, as well as the pathogenesis of the so-called placental obstetric complications, including severe preeclampsia.

Key words: thrombotic microangiopathy, hemostasis, hemolytic anemia, pregnancy, HELLP syndrome.

REFERENCES

1. Kentouche K., Voigt A., Schleussner E., Schneppenheim R., Budde U., Beck J.F., Stefańska-Windyga E., Windyga J. Pregnancy in Upshaw-Schulman syndrome. Hamostaseologie, 2013, vol. 33, no. 2, pp. 144-148. DOI: 10.5482/HAMO-13-04-0025.

2. Torok T.J., Holman R.C., Chorba T.L. Increasing mortality from thrombotic thrombocytopenic purpura in the United States – Analysis of national mortality data, 1968-1991. American Journal of Hematology, 1995, vol. 50, no. 2, pp. 84-90. DOI: 10.1002/ajh.2830500203.

3. Furlan M., Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: The role of von Willebrand factor-cleaving protease. Best Practice and Research in Clinical Haematology, 2001, vol. 14, no. 2, pp. 437-454. DOI: 10.1053/beha.2001.0142.

4. Ruggenenti P., Noris M., Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney International, 2001, vol. 60, no. 3, pp. 831-846. DOI: 10.1046/j.1523-1755.2001.060003831.x.

5. Moake J.L., Rudy C.K., Troll J.H., et al. Unusually large plasma factor VIII: vonWillebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. New England Journal of Medicine, 1982, vol. 307, no. 23, pp. 1432-1435.

6. Raife T., Montgomery R. New aspects in the pathogenesis and threatment of thrombotic thrombocytopenic purpura and hemolytic uremic synfrome. Reviews in Clinical and Experimental Hematology, 2001, vol. 5, no. 3, pp. 536-561.DOI: 10.1046/j.1468-0734.2001.00044.x.

7. Furlan M., Lammle B.Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Bailliere’s Clinical Haematology, 1998, vol. 11, no. 2, pp. 509-14.

8. Loirat C. Post-diarrhea hemolytic-uremic syndrome: Clinical aspects. Archives de Pediatrie, 2001, vol. 8, Suppl. 4, pp. 776-784. DOI: 10.1016/S0929-693X(01)80196-2. (in French).

9. Lammle B., Kremer J., Studt J.D., et al. Thrombotic thrombocytopenic purpura. Hematology Journal, 2004, vol. 5, Suppl 3, pp. S6-S11.

10. Schaller M., Studt J.-D., Voorberg J., Kremer Hovinga JA. Acquired thrombotic thrombocytopenic purpura development of an autoimmune response. Hamostaseologie, 2013, vol. 33, no. 2, pp. 121-130. DOI: 10.5482/HAMO-12-12-0023.

11. Schiphorst R.H., van de Kar N.C., van den Heuvel L.P. From gene to disease; congenital thrombotic thrombocytopenic purpura due to mutations in the ADAMTS13 gene. Nederlands Tijdschrift voor Geneeskunde, 2003, vol. 147, no. 49, pp. 2422-2424. (in Dutch).

12. Furlan M., Lammle B.Splenectomy in thrombotic thrombocytopenic purpura [2]. American Journal of Hematology, 2000, vol. 64, no. 1, p. 79.

13. Furlan M. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Expert Review of Cardiovascular Therapy, 2003, vol. 1, no. 2, pp. 243-255.

14. Tsai H.-M. Molecular mechanisms in thrombotic thrombocytopenic purpura. Seminars in Thrombosis and Hemostasis, 2004, vol. 30, no. 5, pp. 549-557. DOI: 10.1055/s-2004-835675.

15. Remuzzi G., Galbusera M., Salvadori M., et al. Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney International, 1996, vol. 49, no. 1, pp. 282-286.

16. Hamasaki K., Mimura T., Kanda H., et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: A case report and literature review. Clinical Rheumatology, 2003, vol. 22, no. 4-5, pp. 355-358. DOI: 10.1007/s10067-003-0742-1.

17. Karpman D., Tati R. Complement activation in thrombotic microangiopathy. Hamostaseologie, 2013, vol. 33, no 2, pp. 96-104. DOI: 10.5482/HAMO-12-12-0025.

18. Mitra D., Jaffe E.A., Weksler B., et al. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood, 1997, vol. 89, no. 4, pp. 1224-1234.

19. Lammle R., Hovinga J. A. K., Alberio L. Thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2005, vol. 3, no. 8, pp. 1663-1675. DOI: 10.1111/j.1538-7836.2005.01425.x.

20. Zheng X.L. Structure-function and regulation of ADAMTS-13 protease. Journal of Thrombosis and Haemostasis, 2013, vol. 11, Suppl. 1, pp. 11-23. DOI: 10.1111/jth.12221.

21. Miyata T., Kokame K., Matsumoto M., Fujimura Y. ADAMTS13 activity and genetic mutations in Japan. Hamostaseologie, 2013, vol. 33, no. 2, pp. 131-137. DOI: 10.5482/HAMO-12-11-0017.

22. George J.N. Thrombotic thrombocytopenic purpura: A syndrome that keeps evolving. Journal of Clinical Apheresis, 2004, vol. 19, no. 2, pp. 63-65. DOI: 10.1002/jca.20008.

23. George J.N., Vesely S.K., Terrell D.R., et al. The Oklahoma Thrombotic Thrombocytopenic Purpura-Haemolytic Uraemic Syndrome Registry: A model for clinical research, education and patient care. Hamostaseologie, 2013, vol. 33, no. 2, pp. 105-112. DOI: 10.5482/HAMO-12-10-0016.

24. Studt J.D., Hovinga J.A., Radonic R., et al. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood, 2004, vol. 103, no. 11, pp. 4195-4197. DOI:10.1182/blood-2003-11-3888.

25. Lian E.C. Thrombotic thrombocytopenic purpura – A syndrome caused by multiple pathogenetic mechanisms. Investigacion Clinica, 2001, vol. 42, Suppl. 1, pp. 75-86.

26. Berns J.S., Kaplan B.S., Mackow R.C., Hefter L.G.Inherited hemolytic uremic syndrome in adults. American Journal of Kidney Diseases, 1992, vol. 19, no. 4, pp. 331-334.

27. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. New England Journal of Medicine, 1991, vol. 325, no. 6, pp. 393-397.

28. Alberio L. My patient is thrombocytopenic! Is (s)he? Why? And what shall I do?: A practical approach to thrombocytopenia. Hamostaseologie, 2013, vol. 33, no. 2, pp. 83-94. DOI: 10.5482/HAMO-13-01-0003.

29. Kremer H.J.A., Studt J.D., Lammle B. The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP). Pathophysiology of Haemostasis and Thrombosis, 2003, vol. 33, no. 5-6, pp. 417-421. DOI: 10.1159/000083839.

30. Furlan M., Lammle B. Assays of von Willebrand factor-cleaving protease: A test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura. Seminars in Thrombosis and Hemostasis, 2002, vol. 28, no. 2, pp. 167-172. DOI: 10.1055/s-2002-27819.

31. Dong J.F., Whitelock J., Bernardo A., Ball C., Cruz M.A.Variations among normal individuals in the cleavage of endothelial-derived ultra-large von Willebrand factor under flow. Journal of Thrombosis and Haemostasis, 2004, vol. 2, no. 8, pp. pp. 1460-1466. DOI: 10.1111/j.1538-7836.2004.00830.x.

32. Downes K.A., Yomtovian R., Tsai H.M., et al. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. Journal of Clinical Apheresis, 2004, vol. 19, no. 2, pp. 86-89. DOI: 10.1002/jca.20007.

33. Tsai H.M., Shulman K.Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. European Journal of Haematology, 2003, vol. 70, no. 3, pp. 183-185. DOI: 10.1034/j.1600-0609.2003.00026.x

34. McMinn J.R., George J.N. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. Journal of Clinical Apheresis, 2001, vol. 16, no. 4, pp. 202-209. DOI: 10.1002/jca.10005.

35. McCrae K.R., Cines D.B.Thrombotic microangiopathy during pregnancy. Seminars in Hematology, 1997, vol. 34, no. 2, pp. 148-158.

36. Bell W.R., Kickler T.S.Thrombocytopenia in pregnancy. Rheumatic Disease Clinics of North America, 1997, vol. 23, no. 1, pp. 183-194. DOI: 10.1016/S0889-857X(05)70322-7.

37. Yarranton H., Machin S.J. An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura. Current Opinion in Neurology, 2003, vol. 16, no. 3, pp. 367-373. DOI:10.1097/00019052-200306000-00018.

38. Knöbl P.N. Treatment of thrombotic micro-angiopathy with a focus on new treatment options. Hamostaseologie, 2013, vol. 33, no. 2, pp. 149-159. DOI: 10.5482/HAMO-13-01-0004.

39. Bell W.R., Braine H.G., Ness P.M., Kickler T.S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. New England Journal of Medicine, 1991, vol. 325, no. 6, pp. 398-403.

40. Mant M.J., Turner A.R., Bruce D., Ritchie C., Larratt L.M.Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolonged plasma exchange dependency. American Journal of Hematology, 1999, vol. 62, no. 1, pp. 56-57.

41. Yomtovian R., Niklinski W., Silver B., Sarode R., Tsai H.M.Rituximab for chronic recurring thrombotic thrombocytopenic purpura: A case report and review of the literature. British Journal of Haematology, 2004, vol. 124, no. 6, pp. 787-795. DOI:10.1111/j.1365-2141.2004.04836.x.

42. Vanhoorelbeke K., De Meyer S.F. Animal models for thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2013, vol. 11, Suppl. 1, pp. 2-10. DOI: 10.1111/jth.12255.